XERIS PHARMACEUTICALS INC Comprehensive Income
XERIS PHARMACEUTICALS INC reported Comprehensive Income of -$27.52 million for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-05.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2021-08-05
- XERIS PHARMACEUTICALS INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2021-06-30 was -$27.52M.
- XERIS PHARMACEUTICALS INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2021-03-31 was -$18.43M.
- XERIS PHARMACEUTICALS INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2020-09-30 was -$108.00K.
- XERIS PHARMACEUTICALS INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2020-06-30 was -$24.00M, a 34875.36% decline year-over-year.
- XERIS PHARMACEUTICALS INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2020 was -$37.00K, a 138.95% decline from fiscal 2019.
- XERIS PHARMACEUTICALS INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2019 was $95.00K.
- XERIS PHARMACEUTICALS INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2018 was -$52.00K.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2021-06-30 | -$27.52M 10-Q · filed 2021-08-05 | -$45.95M 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | -$18.43M 10-Q · filed 2021-05-13 | ||||
| 2020-12-31 | -$37.00K 10-K · filed 2021-03-09 | ||||
| 2020-09-30 | -$108.00K 10-Q · filed 2020-11-09 | -$24.10M derived: sum of 2 quarters · filed 2021-08-05 | -$53.27M derived: sum of 3 quarters · filed 2021-08-05 | ||
| 2020-06-30 | -$24.00M 10-Q · filed 2021-08-05 | $104.00K 10-Q · filed 2020-08-10 | -$53.16M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$29.17M 10-Q · filed 2021-05-13 | $17.00K 10-Q · filed 2020-08-10 | |||
| 2019-12-31 | $95.00K 10-K · filed 2021-03-09 | ||||
| 2019-09-30 | -$23.00K 10-Q · filed 2020-11-09 | $46.00K derived: sum of 2 quarters · filed 2020-11-09 | $97.00K derived: sum of 3 quarters · filed 2020-11-09 | ||
| 2019-06-30 | $69.00K 10-Q · filed 2020-11-09 | $120.00K derived: sum of 2 quarters · filed 2020-11-09 | |||
| 2019-03-31 | $51.00K 10-Q · filed 2020-11-09 | ||||
| 2018-12-31 | -$52.00K 10-K · filed 2020-03-12 |